NovaThera Ltd announces appointment of Dr Francis Pinto as a Non Executive Director

Cambridge, UK, Tuesday, November 01, 2005 – NovaThera Limited (“NovaThera”) today announced that Dr Francis Pinto had joined its Board as a Non Executive Director.

Dr Pinto is a physician with over 40 years of global experience in the healthcare industry, with extensive experience in research & product development and business turnarounds. Prior assignments include Abbott, Pfizer, BMS and a board directorship with Glaxo Group Limited in the UK. Currently he is the Chief Executive of the Dutch biotechnology firm Pharming N.V. and Chairman of the Xandev Foundation.

“We are delighted to welcome someone with the expertise of Dr Pinto to the NovaThera Board. This represents another significant step in the growth of NovaThera into a major player in the developing regenerative medicine industry” said Dr Gareth Roberts, Director and Chief Executive of NovaThera.

“NovaThera has an exciting suite of technologies with immediate, medium and long term potential in the regenerative medicine field, an area of the life sciences with huge potential for the treatment of a wide range of diseases currently afflicting humans. I am very pleased to join the Board of NovaThera and greatly look forward to working with the current Board and Management towards the further development of the Company” said Dr Pinto.

NovaThera has recently announced partnerships to develop products based on TheraGlass®, its novel biomaterials technology, with Advanced Bio-Technologies, Inc. and Pharming N.V. The first of these products in the wound care field will be launched by Advanced Bio-Technologies, Inc. in the second half of 2006. Additionally, preclinical work on several combination Pharming products has commenced.

* * * * * *

NovaThera Ltd. (“NovaThera”) is a spin-out company of Imperial College London. It specializes in pioneering applications of biomaterials and stem cell biology to regenerative medicine and tissue engineering to provide innovative therapeutic solutions. NovaThera has a relationship with Imperial College to continue commercialization of the current and future technologies emanating from the Tissue Engineering and Regenerative Medicine Centre (“TERM”) of Imperial College London, a world-class research center combining biology, biomaterials and bio-photonics expertise. For more information about NovaThera please visit www.novathera.com.